India’s Biocon Plans Adding More Than $39 Million In R&D, 300 Scientists
This article was originally published in PharmAsia News
Executive Summary
Indian biotechnology firm Biocon said it has invested more than $39 million in a research-and-development effort within the Biocon Research Center to support in-house drug research, focusing on diabetes and other chronic diseases.